Asher Biotherapeutics, Inc. aims to get around the problem of pleiotropy – engagement of a target across a variety of cells in the body, causing unintended side effects – by developing cell-targeted immunotherapies that engage two targets on the same immune cell. The company said on 1 September that it closed a $108m series B venture capital round to advance AB248, an interleukin-2 (IL-2) mutein targeting CD8-positive T-cells, into the clinic and to progress additional programs.
Asher Bio Raises $108m For Immune Cell-Specific Therapies
Series B Follows $55m Series A Round In March
With a CD8-targeting IL-2 mutein as its lead program, the start-up is developing cis-targeted immunotherapies that selectively target two molecules on the same immune cell for improved efficacy and safety.
More from Financing
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
• By
Public Company Edition: Stock valuations are falling due to political, economic and regulatory uncertainty, resulting in fewer large public offerings, more alternative financings and cost cuts. Carisma, Tenaya, BioAtla, Arbutus, Nkarta, Alector and Adaptimmune announced layoffs.
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
More from Business
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.